Financial Services
Tekla Life Sciences Investors(HQL)
Live Price
Offline$16.51
-1.61% today
1Y Change
+46.00%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $530.00M
- Revenue Growth
- -0.3%
- EPS Growth
- -2.6%
- Dividend Yield
- 10.9%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tekla Life Sciences Investors (HQL) is a Financial Services stock with a market cap of $530.00M and listed on NYSE. The stock last traded around $16.51 and up 46.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -0.3%, EPS growth of -2.6%, a dividend yield of 10.9%. What stands out right now is revenue -0.3%, EPS -2.6%, free cash flow 0.0% with operating margin 286.9% and ROIC 16.6%. The dividend matters to the case here, with a current yield around 10.9%. Valuation already assumes a fairly strong business story at P/E 5.9 and price/sales 17.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines HQL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.3% vs +3.4% peer median
Operating Margin
Above sector median
+286.9% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Jun 24, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.3% and EPS is at -2.6%, with operating margin around 286.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 10.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.0% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Jun 24, 2025 | โ | -0.1% | +2.0% | +4.5% |
2024 Dec 9, 2024 | โ | -0.1% | +2.0% | +4.5% |
2024 Aug 6, 2024 | โ | -0.1% | +2.0% | +4.5% |
Benchmark Edge
HQL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HQL
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HQL Max Drawdown
-10.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HQL and SPY.
Company Overview
Tekla Life Sciences Investors
New York Stock Exchange
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
- Leadership
- Daniel R. Omstead
- IPO Date
- May 1, 1992
- Street Address
- 100 Federal Street
- Mailing
- Philadelphia, MA, 02110
- Region
- Philadelphia, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 772 8500
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 5.9
- EV/EBITDA
- 6.2
- Price/Sales
- 17.8
- Price/Book
- 1.0
Growth
- Revenue
- -0.3%
- EPS
- -2.6%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 30.8%
- Operating Margin
- 286.9%
- Net Margin
- 286.9%
- ROE
- 18.8%
- ROIC
- 16.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.